Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial
Huang J, Chen A, Jin H, Liu F, Hei G, Teng Z, Xiao J, Wu R, Zhao J, Davis JM, Shao P, Smith RC
The Journal of clinical psychiatry · 8 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-01-20 · J Clin Psychiatry · vol. 86 · número 1
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 17 citas · más que el 99% de estudios similares · 10.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 22 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Schizophrenia research and treatment · Tryptophan and brain disorders · Treatment of Major Depression
- Palabras clave
- sulforaphane, schizophrenia, negative symptoms, antipsychotic drugs, adjunctive therapy, histone deacetylase inhibition, oxidative stress, antioxidants, PANSS, glucoraphanin, depression, cognitive function
- MeSH
- humans, isothiocyanates, sulfoxides, antipsychotic agents, treatment outcome, drug therapy, combination, double-blind method, schizophrenia, adult, middle aged, female, male
12 autores
- Jing Huang🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- AnMei Chen🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Hua Jin🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Fangkun Liu🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Gangrui Hei🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Ziwei Teng🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Jingmei Xiao🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Renrong Wu🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Jingping Zhao🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- John M. Davis🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Ping Shao🇺🇸🇨🇳Nathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
- Robert C. Smith🇺🇸🇨🇳 · autor de correspondenciaNathan Kline Institute for Psychiatric Research; Central South University; University of California San Diego; University of Illinois Chicago; NYU Langone Health; VA San Diego Healthcare System; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Zhengzhou University; Xiangya Hospital Central South University; New York University; Columbia University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective: There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor. We conducted a 24-week, double-blind, placebo-controlled study, in Hunan, China, to assess the effect of high-dose sulforaphane (Nutramax extra strength sulforaphane tablets glucoraphanin content 30 mg/ tablet) on reducing negative symptoms in antipsychotic-treated patients with schizophrenia.Methods: Participants were recruited from August 2020 to August 2022 and met DSM-5 criteria for schizophrenia. Participants were randomly assigned (2:1) to receive antipsychotics plus sulforaphane (1,700 mg Avmacol Extra Strength sulforaphane daily) or antipsychotics plus placebo for 24 weeks. Fifty-three patients treated with sulforaphane and 24 patients treated with placebo who had at least 1 postintervention clinical scale evaluation were analyzed. The primary outcome measure was change in the Positive and Negative Syndrome Scale (PANSS) negative symptoms.Results: Sulforaphane-treated patients showed a significantly greater decrease in PANSS negative symptom total score (P = .01) and PANSS negative factor score (P = .02) than placebo-treated patients, with the most prominent difference occurring at 24 weeks (P ≤ .001) with a large effect size at this time point (d = 0.8). Sulforaphane's effect on decreasing negative symptoms was not mediated by changes in scores of depression or cognitive factors on the PANSS.Conclusions: The results of this study suggest that add-on high-dose sulforaphane may reduce negative symptoms in patients with schizophrenia. The clinical significance of this reduction in negative symptoms needs further evaluation.Trial Registration: ClinicalTrials.gov identifier: NCT04521868.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.